Cynata Therapeutics Limited CYYNF

Full chart Compare

Set alert

0.01 USD 0.00 (+0.00%)

At closeNov 10, 2026, 4:00 PM EST

0.11 Day range 0.11

0.0014 52-week range 0.2225

YTD: -95.20%
1 year: -93.90%

News

4 months ago seekingalpha.com Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
9 months ago seekingalpha.com Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
10 months ago defenseworld.net Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
10 months ago defenseworld.net Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Exelixis (NASDAQ: EXEL - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies…
1 year ago seekingalpha.com Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript Cynata Therapeutics Limited (OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST Company…
1 year ago seekingalpha.com Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript Cynata Therapeutics Limited (OTCPK:CYYNF) Q4 2025 Earnings Conference Call August 4, 2025 9:00 PM ET Company Participants Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer…
1 year ago seekingalpha.com Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Company Participants Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and…
5 years ago seekingalpha.com Longeveron Seeks $25 Million IPO For Anti-Aging Efforts Longeveron Seeks $25 Million IPO For Anti-Aging Efforts